

10/533833

JC06 Rec'd PCT/PTO 03 MAY 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP2003/014101
Filed: Intl. Filing 05 NOVEMBER 2003
1st Inventor: Masahiro KAJINO
For: Receptor Regulator
Atty. Dkt. No. 3116 US0P

Art Unit: tba
Examiner: tba
Allowed:
Batch:
Paper No.:

Information Disclosure Statement

MAIL STOP PCT
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.


Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitted,

Dated  5/10/05

(847) 383-3372
(847) 383-3391



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

10/533833

JC06 Rec'd PCT/PTO 03 MAY 2009

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	Based on PCT/JP03/14101
		Filing Date	Intl. Filing 05 NOV 2003
		First Named Inventor	Masahiro KAJINO
		Art Unit	tba
		Examiner Name	tba
Sheet	2	of	2
		Attorney Docket Number	3116 US0P

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A8	L.V. KUDZMA, et al., "4-Phenyl- and 4-Heteroaryl-4-anilidopiperidines. A Novel Class of Analgesic and Anesthetic Agents", J. Med. Chem., (1989, pp. 2534-2542, Vol. 32.	
	A9	N. SAKURA, et al., "Structure-Activity Relationships of Neuromedin U. IV. Absolute Requirement of the Arginine Residue at Position 7 of Dog Neuromedin U-8 for Contractile Activity", Chem. Pharm. Bull., (2000), pp. 1166-1170, Vol. 48, No. 8.	
	A10	M.J. COLEMAN, et al., "A Convenient Method for the N-Acylation and Esterification of Hindered Amino Acids: Synthesis of Ultra Short Acting Opioid Agonist, Remifentanyl", Synlett, (1999), pp. 1923-1224, No. 12.	
	A11	N. MINAMINO, et al., "Neuromedin U-8 and U-25: Novel Uterus Stimulating and Hypertensive Peptides Identified in Porcine Spinal Cord", Biochemical and Biophysical Research Communications, (1985), pp. 1078-1085, Vol. 130, No. 3.	
	A12	L.K. MALENOWICZ, et al., "Effects of Neuromedin U-8 on the Rat Pituitary-Adrenocortical Axis", in vivo, (1993), pp. 419-422, Vol. 7.	
	A13	D.R. Brown, et al., "Neuromedin U Octapeptide Alters Ion Transport in Porcine Jejunum", European Journal of Pharmacology, (1988), pp. 159-162, Vol. 155.	
	A14	S. SUMI, et al., "Effect of Synthetic Neuromedin U-8 and U-25, Novel Peptides Identified in Porine Spinal Cord, on Splanchnic Circulation in Dogs", Life Sciences, (1987), pp. 1585-1590, Vol. 41.	
	A15	C.P. TAN, et al., "Cloning and Characterization of a Human and Murine T-Cell Orphan G-Protein-Coupled Receptor Similar to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1998), pp. 223-229, Vol. 52.	
	A16	K. K. McKEE, et al., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1997), pp. 426-434, Vol. 46.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.